JW Therapeutics announced the initiation of clinical study of Carteyva® for first-line treatment in patients with high-risk large B-cell lymphoma and the first patient infusion.
JW Therapeutics announced the initiation of clinical study of Carteyva® for first-line treatment in patients with high-risk large B-cell lymphoma and the first patient infusion.